Precipio, Inc. (PRPO)
| Market Cap | 8.27M |
| Revenue (ttm) | 15.20M |
| Net Income (ttm) | -5.85M |
| Shares Out | 1.37M |
| EPS (ttm) | -4.51 |
| PE Ratio | n/a |
| Forward PE | 15.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,308 |
| Open | 6.21 |
| Previous Close | 6.18 |
| Day's Range | 5.80 - 6.21 |
| 52-Week Range | 4.75 - 14.80 |
| Beta | 1.25 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 10, 2024 |
About PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut. [Read more]
Financial Performance
In 2023, Precipio's revenue was $15.20 million, an increase of 61.46% compared to the previous year's $9.41 million. Losses were -$5.85 million, -52.04% less than in 2022.
Financial StatementsNews
Precipio Announces Year end 2023 Shareholder Update Call
NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5...
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown fro...
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into a distribution agreement with Cardinal Health for i...
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
Results clearly demonstrate the business's ability to reach breakeven in the near future Results clearly demonstrate the business's ability to reach breakeven in the near future
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sa...
Precipio Announces Christina Valauri joins the Board of Directors
Douglas Fisher, MD will step down as Director, and remain as a board observer Douglas Fisher, MD will step down as Director, and remain as a board observer
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forwar...
Precipio Announces Q3-2023 Shareholder Update Call
NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00...
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3...
Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023
Company anticipates current cash levels sufficient to reach breakeven Company anticipates current cash levels sufficient to reach breakeven
Precipio Continues to Sign New HemeScreen™ Customers
NEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen ...
Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven
Higher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6M Higher pathology revenues and lower cost structure drive down product revenue breakeven po...
Precipio Takes Final Step Towards Regaining Nasdaq Compliance
NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of outs...
Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan
NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces its Pathology Division has in August exceeded the monthly breakeven ...
Precipio Announces Q2-2023 Shareholder Update Call
NEW HAVEN, Conn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2023 corporate update call on August 17th at 5:00 PM ET.
Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel
NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its new quantitative BCR-ABL 2.0 panel, with features m...
Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven
These efficiencies plus revenue growth expected to continue the positive momentum These efficiencies plus revenue growth expected to continue the positive momentum
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023
Revenue growth and customer pipeline advance the Company towards breakeven Revenue growth and customer pipeline advance the Company towards breakeven
Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling Use of HemeScreen® technology enables diagnosis without the need for painful, invasive sampling
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
New panel will enable rapid, precise genetic profiling of patients with deadly disease New panel will enable rapid, precise genetic profiling of patients with deadly disease
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced it has entered into securities purchase agreements with cert...
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3 Independent of revenue growth, these Projects expected to decrease cash burn by 25% in Q3
Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care Panel-Based Approach of Driver Mutation Detection Proves Crucial for Patient Care
Precipio Shares Growth Catalysts For HemeScreen
NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be discussing on today's shareholders call several growth catalysts that...
Precipio Announces Q1-2023 Shareholder Update Call
NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET.